Trial Outcomes & Findings for Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients (NCT NCT06584734)

NCT ID: NCT06584734

Last Updated: 2026-05-01

Results Overview

Classification of left ventricular diastolic function into ordinal grades based on the 2016 ASE/EACVI guidelines. Classification is determined by integrating E/A ratio, average E/e' ratio, indexed left atrial volume (LAVi), and tricuspid regurgitation (TR) velocity. Grade 1 (mild, impaired relaxation) is the least severe; Grade 2 (moderate, pseudonormal filling) represents intermediate severity; Grade 3 (severe, restrictive filling) is the most severe. Grading criteria: Grade 1 (mild - impaired relaxation): E/A \< 0.8, average E/e' ≤ 14, LAVi ≤ 34 ml/m², TR velocity ≤ 2.8 m/s; fewer than 2 positive criteria. Grade 2 (moderate - pseudonormal filling): E/A 0.8-2.0, with ≥ 2 of the following positive: average E/e' \> 14, LAVi \> 34 ml/m², TR velocity \> 2.8 m/s. Grade 3 (severe - restrictive filling): E/A \> 2.0, or E/A 0.8-2.0 with all three criteria positive.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

30 participants

Primary outcome timeframe

16 weeks (end of control period) and 32 weeks (end of intervention)

Results posted on

2026-05-01

Participant Flow

The target population consisted on prevalent chronic kidney disease patients treated in the hemodialysis center at the National Institute of Cardiology between September 2023 and September 2024

Participants were screened for a baseline echocardiographic window adequate for diastolic function measurement and their physical ability to perform stationary cycling during hemodialysis. Patients were excluded if they experienced a major cardiovascular event or decompensated heart failure in the 3 months prior to enrollment

Participant milestones

Participant milestones
Measure
Prevalent Patients in Hemodiafiltration
Prevalent patients having hemodiafiltration sessions 3 times a week, they used to do intradialytic exercise but this exercise was neither measured, quantified, or supervised, so they were withdrawn from this exercise for 16 weeks and after this time, 16 weeks of structured, measured and supervised intradialytic exercise was introduced.
1. Control Phase (Rest) - 16 weeks
STARTED
30
1. Control Phase (Rest) - 16 weeks
COMPLETED
21
1. Control Phase (Rest) - 16 weeks
NOT COMPLETED
9
2. Intradialytic exercise - 16 weeks
STARTED
21
2. Intradialytic exercise - 16 weeks
COMPLETED
21
2. Intradialytic exercise - 16 weeks
NOT COMPLETED
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Prevalent Patients in Hemodiafiltration
Prevalent patients having hemodiafiltration sessions 3 times a week, they used to do intradialytic exercise but this exercise was neither measured, quantified, or supervised, so they were withdrawn from this exercise for 16 weeks and after this time, 16 weeks of structured, measured and supervised intradialytic exercise was introduced.
1. Control Phase (Rest) - 16 weeks
Renal Transplant
3
1. Control Phase (Rest) - 16 weeks
Surgery
2
1. Control Phase (Rest) - 16 weeks
Hospitalization during study
3
1. Control Phase (Rest) - 16 weeks
Vascular access disfunction
1

Baseline Characteristics

Of the 21 enrolled participants, questionnaire data were available and analyzable for 13 participants. Data from 8 participants were excluded due to incomplete or non-interpretable responses, limiting valid scoring of the instrument.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Prevalent Patients in Hemodiafiltration
n=21 Participants
Prevalent patients having hemodiafiltration sessions 3 times a week, they used to do intradialytic exercise but this exercise was neither measured, quantified, or supervised, so they were withdrawn from this exercise for 16 weeks and after this time, 16 weeks of structured, measured and supervised intradialytic exercise was introduced.
Age, Continuous
39.18 Years
STANDARD_DEVIATION 12.9 • n=21 Participants
Sex: Female, Male
Female
12 Participants
n=21 Participants
Sex: Female, Male
Male
9 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
21 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants
n=21 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=21 Participants
Medication
On antihypertensive therapy
1 Participants
n=21 Participants
Medication
Vitamin D analogues
2 Participants
n=21 Participants
Medication
Phosphate binders
1 Participants
n=21 Participants
Medication
Erythropoietin
0 Participants
n=21 Participants
Dry-Weight Body Mass Index
23.78 kg/m^2
STANDARD_DEVIATION 5 • n=21 Participants
Dialysis vintage
314 weeks
n=21 Participants
Comorbidities
Hypertension
10 Participants
n=21 Participants
Comorbidities
Type 2 diabetes
4 Participants
n=21 Participants
Comorbidities
Ischemic Cardiopathy
4 Participants
n=21 Participants
Comorbidities
Hyperparathyroidism
3 Participants
n=21 Participants
Etiology
Unknown
8 Participants
n=21 Participants
Etiology
Glomerulopathies
8 Participants
n=21 Participants
Etiology
Diabetic Kidney Disease
2 Participants
n=21 Participants
Etiology
Other
3 Participants
n=21 Participants
Laboratory values
Hemoglobin
10.4 g/dl
n=21 Participants
Laboratory values
Albumin
4.32 g/dl
n=21 Participants
Left Ventricular Diastolic Function Category
Grade 1
15 Participants
n=21 Participants
Left Ventricular Diastolic Function Category
Grade 2
5 Participants
n=21 Participants
Left Ventricular Diastolic Function Category
Grade 3
1 Participants
n=21 Participants
Left Atrial Reservoir Strain (LASr)
29.5 Percentage
STANDARD_DEVIATION 9.2 • n=21 Participants
Left Ventricular Global Longitudinal Strain (GLS)
-16.9 Percentage
STANDARD_DEVIATION 2.9 • n=21 Participants
Automated Left Ventricular Ejection Fraction (AutoLVEF)
59 Percentage
STANDARD_DEVIATION 2.8 • n=21 Participants
Tricuspid Annular Plane Systolic Excursion (TAPSE)
21.14 Millimeters (mm)
STANDARD_DEVIATION 3 • n=21 Participants
Distance Covered in the Six-Minute Walk Test (6MWT)
473 Meters (m)
n=21 Participants
Physical Activity Level (GPPAQ)
Inactive
3 Participants
n=13 Participants • Of the 21 enrolled participants, questionnaire data were available and analyzable for 13 participants. Data from 8 participants were excluded due to incomplete or non-interpretable responses, limiting valid scoring of the instrument.
Physical Activity Level (GPPAQ)
Moderately Inactive
3 Participants
n=13 Participants • Of the 21 enrolled participants, questionnaire data were available and analyzable for 13 participants. Data from 8 participants were excluded due to incomplete or non-interpretable responses, limiting valid scoring of the instrument.
Physical Activity Level (GPPAQ)
Moderately Active
4 Participants
n=13 Participants • Of the 21 enrolled participants, questionnaire data were available and analyzable for 13 participants. Data from 8 participants were excluded due to incomplete or non-interpretable responses, limiting valid scoring of the instrument.
Physical Activity Level (GPPAQ)
Active
3 Participants
n=13 Participants • Of the 21 enrolled participants, questionnaire data were available and analyzable for 13 participants. Data from 8 participants were excluded due to incomplete or non-interpretable responses, limiting valid scoring of the instrument.
Ratio of Early Mitral Inflow to Mitral Annular Velocity (E/e' ratio)
9.03 ratio
STANDARD_DEVIATION 3.0 • n=21 Participants
Mitral Inflow E/A Ratio
1.2 ratio
STANDARD_DEVIATION 0.39 • n=21 Participants
Left Atrial Volume Index (LAVi)
31.7 ml/m^2
STANDARD_DEVIATION 8.9 • n=21 Participants
Tricuspid regurgitation velocity
2.62 cm/s
STANDARD_DEVIATION 0.5 • n=21 Participants

PRIMARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Classification of left ventricular diastolic function into ordinal grades based on the 2016 ASE/EACVI guidelines. Classification is determined by integrating E/A ratio, average E/e' ratio, indexed left atrial volume (LAVi), and tricuspid regurgitation (TR) velocity. Grade 1 (mild, impaired relaxation) is the least severe; Grade 2 (moderate, pseudonormal filling) represents intermediate severity; Grade 3 (severe, restrictive filling) is the most severe. Grading criteria: Grade 1 (mild - impaired relaxation): E/A \< 0.8, average E/e' ≤ 14, LAVi ≤ 34 ml/m², TR velocity ≤ 2.8 m/s; fewer than 2 positive criteria. Grade 2 (moderate - pseudonormal filling): E/A 0.8-2.0, with ≥ 2 of the following positive: average E/e' \> 14, LAVi \> 34 ml/m², TR velocity \> 2.8 m/s. Grade 3 (severe - restrictive filling): E/A \> 2.0, or E/A 0.8-2.0 with all three criteria positive.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Left Ventricular Diastolic Function Category
Grade 1
15 Participants
15 Participants
Left Ventricular Diastolic Function Category
Grade 2
5 Participants
5 Participants
Left Ventricular Diastolic Function Category
Grade 3
1 Participants
1 Participants

PRIMARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Peak longitudinal deformation of the left atrium during the reservoir phase measured by 2D speckle tracking echocardiography. Expressed as a percentage (%). Higher values indicate better left atrial reservoir function and, indirectly, less elevation in left ventricular filling pressures.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Left Atrial Reservoir Strain (LASr)
26.2 Percentage
Standard Deviation 11.1
30.4 Percentage
Standard Deviation 6.4

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Assessment of myocardial deformation using 2D speckle tracking echocardiography. Values are expressed as a negative percentage (%); more negative values indicate better longitudinal contraction (e.g., -17.4% is better than -15.5%)

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Left Ventricular Global Longitudinal Strain (GLS)
-15.5 Percentage
Standard Deviation 3.9
-17.4 Percentage
Standard Deviation 2.38

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Automated left ventricular ejection fraction (%), calculated using automated contour detection software applied to 2D echocardiographic images. Represents the proportion of blood ejected from the left ventricle with each heartbeat. Higher values indicate better left ventricular systolic function; values \>= 52% are considered within normal range.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Automated Left Ventricular Ejection Fraction (AutoLVEF)
56.8 Percentage
Standard Deviation 5.3
59.5 Percentage
Standard Deviation 3.14

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Tricuspid annular plane systolic excursion (TAPSE), measured in millimeters (mm) by M-mode echocardiography at the lateral tricuspid annulus. Reflects right ventricular longitudinal systolic function. Higher values indicate better right ventricular function; values \>= 17 mm are considered within normal range.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Tricuspid Annular Plane Systolic Excursion (TAPSE)
20.6 millimeters (mm)
Standard Deviation 2.6
22.2 millimeters (mm)
Standard Deviation 3.7

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention period)

Non-invasive estimate of left ventricular filling pressure calculated as the ratio of early diastolic mitral inflow velocity (E wave, pulsed-wave Doppler) to the average of septal and lateral mitral annular early diastolic velocities (e', tissue Doppler imaging). Higher values indicate elevated filling pressures.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Ratio of Early Mitral Inflow to Mitral Annular Velocity (E/e' Ratio)
9.98 ratio
Standard Deviation 3.16
10.2 ratio
Standard Deviation 3.86

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention period)

Ratio of early diastolic (E wave) to late diastolic (A wave) mitral inflow velocities measured by pulsed-wave Doppler echocardiography with the sample volume placed at the mitral valve leaflet tips, apical four-chamber view. Reflects left ventricular relaxation and filling patterns.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Mitral Inflow E/A Ratio
1.15 ratio
Standard Deviation 0.44
1.23 ratio
Standard Deviation 0.43

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention period)

Left atrial volume indexed to body surface area (ml/m\^2) measured by the biplane Simpson method using apical four-chamber and two-chamber views. Reflects left atrial structural remodeling as a marker of chronic elevation in left ventricular filling pressures. Lower values indicate less atrial remodeling and are associated with better diastolic function; values \<= 34 ml/m2 are within the normal range per ASE 2016 guidelines.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Left Atrial Volume Index (LAVi)
30.8 ml/m^2
Standard Deviation 10
30.1 ml/m^2
Standard Deviation 8

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention period)

Peak tricuspid regurgitation velocity (cm/s) assessed by continuous-wave Doppler echocardiography, used to estimate right ventricular systolic pressure and pulmonary artery pressure per the 2016 ASE/EACVI diastolic function guidelines. Lower values are associated with lower estimated pulmonary pressures and less severe diastolic dysfunction; values \<= 2.8 m/s are within the normal range.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Tricuspid Regurgitation Velocity
2.95 cm/s
Standard Deviation 0.56
2.80 cm/s
Standard Deviation 0.3

SECONDARY outcome

Timeframe: 16 weeks (end of control period), and 32 weeks (end of intervention)

Population: Of the 21 enrolled participants, questionnaire data were available and analyzable for 13 participants. Data from 8 participants were excluded due to incomplete or non-interpretable responses, limiting valid scoring of the instrument.

General Practice Physical Activity Questionnaire. Self-administered questionnaire for adults consisting of 3 questions assessing type and amount of physical activity at work, during leisure time, and usual walking pace. Classifies patients into 4 levels: Inactive, Moderately Inactive, Moderately Active, and Active. Higher activity levels represent better physical activity status; Active is the most favorable and Inactive is the least favorable category.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=13 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=13 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Physical Activity Level (GPPAQ)
Moderately Inactive
6 Participants
1 Participants
Physical Activity Level (GPPAQ)
Inactive
2 Participants
2 Participants
Physical Activity Level (GPPAQ)
Moderately Active
2 Participants
5 Participants
Physical Activity Level (GPPAQ)
Active
3 Participants
5 Participants

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Total distance in meters (m) that a patient can quickly walk on a flat, hard surface in a period of 6 minutes based on the guidelines of the American and European Thoracic Societies by two medical interns, who are trained to perform the test. It assesses functional capacity and response to the exercise intervention. Greater distances indicate better functional exercise capacity.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Distance Covered in the Six-Minute Walk Test (6MWT)
475 Meters (m)
Interval 428.0 to 516.0
492 Meters (m)
Interval 433.0 to 553.0

SECONDARY outcome

Timeframe: 16 weeks (end of control period), and 32 weeks (end of intervention)

Peak workload (maximal power output) is defined as the highest power output (in watts) achieved during a symptom-limited incremental CPET on a cycle ergometer, corresponding to the last fully completed workload stage or the highest workload maintained for ≥30 seconds. Higher values indicate greater maximal aerobic exercise capacity.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Peak Workload (Maximal Power Output)
72.9 Watts
Standard Deviation 26.1
95.2 Watts
Standard Deviation 32.3

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Power output (watts) achieved during a cardiopulmonary exercise test (CPET) at the point of the first ventilatory threshold (VT1) -- the exercise intensity above which ventilation begins to increase disproportionately to oxygen consumption. Higher values indicate greater aerobic exercise capacity and improved cardiovascular fitness.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Workload at First Ventilatory Threshold (VT1)
33.8 Watts (W)
Standard Deviation 8.0
42.6 Watts (W)
Standard Deviation 10.0

SECONDARY outcome

Timeframe: 16 weeks (end of control period) and 32 weeks (end of intervention)

Maximum rate of oxygen consumption (VO2 max) measured during incremental exercise on a cycle ergometer, expressed in milliliters per kilogram per minute (ml/kg/min). Reflects overall cardiorespiratory fitness and aerobic capacity. Higher values indicate better cardiovascular fitness; values \< 17.5 ml/kg/min in dialysis patients are associated with increased cardiovascular risk.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Peak Oxygen Consumption (VO2 Max)
17.5 ml/kg/min
Standard Deviation 6.6
19.8 ml/kg/min
Standard Deviation 6.3

POST_HOC outcome

Timeframe: Baseline, 16 weeks (end of control period), and 32 weeks (end of intervention)

Left atrial reservoir strain assessed by 2D speckle tracking echocardiography at three study timepoints as a pre-specified sensitivity analysis. Expressed as percentage (%).

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Left Atrial Reservoir Strain (LASr) - Three-Timepoint Sensitivity Analysis
29.5 Percent
Standard Deviation 9.2
26.2 Percent
Standard Deviation 11.1
30.4 Percent
Standard Deviation 6.4

POST_HOC outcome

Timeframe: Baseline, 16 weeks (end of control period), and 32 weeks (end of intervention)

Automated left ventricular ejection fraction assessed by echocardiography using automated contour detection software at three study timepoints as a pre-specified sensitivity analysis. Expressed as percentage (%).

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Automated Left Ventricular Ejection Fraction (AutoLVEF) - Three-Timepoint Sensitivity Analysis
59 Percent (%)
Standard Deviation 2.8
56.8 Percent (%)
Standard Deviation 5.3
59.5 Percent (%)
Standard Deviation 3.14

POST_HOC outcome

Timeframe: Baseline, 16 weeks (end of control period), and 32 weeks (end of intervention)

Ratio of early diastolic (E) to late diastolic (A) mitral inflow velocities measured by pulsed-wave Doppler echocardiography at three study timepoints as a pre-specified sensitivity analysis.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Mitral Inflow E/A Ratio - Three-Timepoint Sensitivity Analysis
1.2 ratio
Standard Deviation 0.39
1.15 ratio
Standard Deviation 0.44
1.23 ratio
Standard Deviation 0.43

POST_HOC outcome

Timeframe: Baseline, 16 weeks (end of control period), and 32 weeks (end of intervention)

Left atrial volume indexed to body surface area (ml/m\^2) measured by biplane Simpson echocardiography at three study timepoints as a pre-specified sensitivity analysis.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Left Atrial Volume Index (LAVi) - Three-Timepoint Sensitivity Analysis
31.7 ml/m^2
Standard Deviation 8.9
30.8 ml/m^2
Standard Deviation 10
30.1 ml/m^2
Standard Deviation 8

POST_HOC outcome

Timeframe: Baseline, 16 weeks (end of control period), and 32 weeks (end of intervention)

Peak tricuspid regurgitation velocity (cm/s) assessed by continuous-wave Doppler echocardiography at three study timepoints as a pre-specified sensitivity analysis

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Tricuspid Regurgitation Velocity - Three-Timepoint Sensitivity Analysis
2.62 cm/s
Standard Deviation 0.5
2.95 cm/s
Standard Deviation 0.56
2.8 cm/s
Standard Deviation 0.3

POST_HOC outcome

Timeframe: Baseline (week 0), 16 weeks (end of control period), and 32 weeks (end of intervention period)

Ratio of early mitral inflow velocity to the average mitral annular velocity (E/e') assessed at three study timepoints as part of the pre-specified echocardiographic sensitivity analysis. Higher values indicate elevated left ventricular filling pressures.

Outcome measures

Outcome measures
Measure
Control Period (Pre-Exercise)
n=21 Participants
Patients receiving standard hemodiafiltration treatment for 16 weeks without any type of exercise program.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Intervention Period (Intradialytic Exercise)
n=21 Participants
Patients undergoing 16 weeks of systematic, prescribed, and supervised intradialytic aerobic exercise (stationary cycling) during hemodiafiltration sessions.
Ratio of Early Mitral Inflow to Mitral Annular Velocity (E/e' Ratio) - Three Timepoint Sensitivity Analysis
9.03 ratio
Standard Deviation 3
9.98 ratio
Standard Deviation 3.16
10.2 ratio
Standard Deviation 3.86

Adverse Events

Patients in Hemodiafiltration

Serious events: 0 serious events
Other events: 19 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Patients in Hemodiafiltration
n=21 participants at risk
Patients having hemodiafiltration sessions 3 times a week, they used to do intradialytic exercise but this exercise was neither measured, quantified, or supervised, so they were withdrawn from this exercise for 16 weeks and after this time, 16 weeks of structured, measured and supervised intradialytic exercise was introduced.
Cardiac disorders
Intradialytic Hypotension
28.6%
6/21 • Number of events 8 • During the 16-week intradialytic exercise intervention period (Period 2).
Adverse events were monitored exclusively during the Intradialytic Exercise Phase (Intervention Period, 16 weeks, 921 hemodialysis sessions) by trained medical staff during and immediately after each exercise session. No adverse event monitoring was conducted during the Control Phase (Period 1), as no exercise intervention was performed during that period and no exercise-related events were expected or recorded.
Nervous system disorders
Headache
47.6%
10/21 • Number of events 30 • During the 16-week intradialytic exercise intervention period (Period 2).
Adverse events were monitored exclusively during the Intradialytic Exercise Phase (Intervention Period, 16 weeks, 921 hemodialysis sessions) by trained medical staff during and immediately after each exercise session. No adverse event monitoring was conducted during the Control Phase (Period 1), as no exercise intervention was performed during that period and no exercise-related events were expected or recorded.
Nervous system disorders
Dizziness
42.9%
9/21 • Number of events 17 • During the 16-week intradialytic exercise intervention period (Period 2).
Adverse events were monitored exclusively during the Intradialytic Exercise Phase (Intervention Period, 16 weeks, 921 hemodialysis sessions) by trained medical staff during and immediately after each exercise session. No adverse event monitoring was conducted during the Control Phase (Period 1), as no exercise intervention was performed during that period and no exercise-related events were expected or recorded.
Musculoskeletal and connective tissue disorders
Muscle cramps
66.7%
14/21 • Number of events 24 • During the 16-week intradialytic exercise intervention period (Period 2).
Adverse events were monitored exclusively during the Intradialytic Exercise Phase (Intervention Period, 16 weeks, 921 hemodialysis sessions) by trained medical staff during and immediately after each exercise session. No adverse event monitoring was conducted during the Control Phase (Period 1), as no exercise intervention was performed during that period and no exercise-related events were expected or recorded.
Gastrointestinal disorders
Nausea
19.0%
4/21 • Number of events 6 • During the 16-week intradialytic exercise intervention period (Period 2).
Adverse events were monitored exclusively during the Intradialytic Exercise Phase (Intervention Period, 16 weeks, 921 hemodialysis sessions) by trained medical staff during and immediately after each exercise session. No adverse event monitoring was conducted during the Control Phase (Period 1), as no exercise intervention was performed during that period and no exercise-related events were expected or recorded.

Additional Information

MSc, MD Salvador Lopez Gil

Instituto Nacional de Cardiologia Ignacio Chavez

Phone: +52 5555732911

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place